Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, blinded, placebo-controlled study evaluating the drug, SUO11248
(SUTENT), for maintenance therapy in advanced urothelial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center